PTC completes ST-920 acquisition, moving Fabry gene therapy toward Q4 BLA

PTC is using its rare-disease commercial and regulatory infrastructure to add late-stage assets with near-term approval potential; ST-920 fits that strategy as a BLA-stage Fabry gene therapy. The company says the product is a “BLA-stage one-time administered AAV gene therapy product candidate for Fabry disease.” 〔0〕

The transaction is now operational, not merely prospective. PTC completed the previously announced agreement with Sangamo to acquire ST-920. 〔1〕 The economic terms were already public: $111 million upfront and up to $100 million tied to accelerated and full FDA approval, so the closing itself does not materially reset expectations.

The real near-term test is regulatory execution. PTC still expects to complete a rolling FDA BLA submission in the fourth quarter of 2026. 〔2〕 That timing was part of the original acquisition thesis, so this filing confirms progress toward the next milestone rather than delivering new clinical evidence or approval.

The asset has meaningful clinical promise, but the filing adds no fresh proof. PTC points to favorable renal-function results and 52-week safety and tolerability from the Phase 1/2 STAAR study. 〔3〕 Those data were already the basis for the planned purchase and BLA strategy; regulatory review, approval, reimbursement, and commercial execution remain ahead.

Bottom line: This removes closing risk and puts ST-920 under PTC’s control, but it is confirmation of an expected transaction rather than a new surprise. The story now depends on the Q4 BLA submission and FDA decision path, not on the acquisition announcement itself.